The Indian pharmaceutical company has been built from an industry that copies patent drugs and manufactures them inexpensively. Now it is counted amongst the industries that are fuelling India's economic growth and holds enormous potential. Indian-based pharmaceutical companies are also predicted to gain considerable market share in the world. It ranks third world wide, in terms of technology, quality and range of medicines manufactured. Indian Pharma Company fulfils around 70 percent of the country's demand all together. Currently, it's estimated to be worth US$4.5 billion, and is growing at nearly 8 to 9 % annually. Due to amended patent act there are an assortment of changes took place in Indian pharma industry. The primary objective of this paper is to study significance of the amended patent act on pharma industry. The paper also allows study of the scope of amended patent act.
Introduction
Pharmaceutical industry in pre-TRIPS period: The Pharmaceutical Industry witnessed a change after the formation of World Trade Organization (WTO) in 1995 when India, being a signatory member of WTO, adopted TradeRelated Aspects of Intellectual Property Rights (TRIPS) Agreement. Indian pharmaceutical company is about 120 years old. Production of modern medicine by indigenous units started with the setting up of Bengal Chemical and Pharmaceutical works in Calcutta (1892), which was followed by the establishment of Alembic Chemical works in Baroda (1907 ) & Bengal Immunity in 1919 At that point of time, the Patents Act of 1911 was in practice, which facilitated patenting all the known and possible processes of manufacturing a drug besides patenting the drug itself. Foreign multinational corporations (MNCs) were quick to take advantage of this provision. They consistently imported bulk drugs from their home countries & produced/mixed formulations in India, contending that locally available bulk drugs were not of desired quality. They also patented heavily in the country. The indigenous firms were legally prevented from manufacturing most of the new drugs introduced by the transnational corporations (TNCs) during the life of the patent secured by the latter, i.e., for 16 years, which could be extended to a maximum of another 10 years if the working of the patent had not been sufficiently remunerative to the patentee. The domestic firms were also forbidden from processing a patented drug into formulations or importing it. As a result, at the time of independence, the industry was dominated by multinational corporations and the prevailing drug prices were among the highest in the world. Between 1947 Between & 1957 , ninety-nine percent of the 1704 drugs & pharmaceutical patents in India were held by foreign multinational enterprises which controlled 80 percent of the market. To study patents & provide suggestions on the type of patent system that India should implement, two expert committees were established in independent India. The Patent Enquiry Committee reported that, "the Indian patent system has failed in its main purpose, namely to stimulate inventions among Indians and to encourage the development and exploitation of new inventions for industrial purposes in the country so as to secure the benefits thereof to the largest section of the public."
The second committee, known as the Ayyangar Committee (1957-59) , noted that foreign patentees were acquiring patents not "in the interests of the economy of the country granting the patent or with a view to manufacture there, but with the object of protecting an export market from competition from rival manufacturers particularly those in other parts of the world". Thus India "is deprived of getting, in many cases, goods at cheaper prices from alternative sources because of the patent protection granted in India". These reports concluded that foreigners held 80-90 per cent of the patents in India and were exploiting the system to achieve monopolistic control of the market.
The committees therefore suggested that a patent system, which focused on access to resources at lower prices, would be beneficial to India. The Patent Act of 1970 was based on the recommendations of these committees. The act found support among domestic firms and various political parties in India. Under this act, only one process that was used in the actual manufacturing could be patented. The period 1970-95, generally known as pre-TRIPS period, was a flourishing phase of Indian pharmaceutical company. 
Pharmaceutical industry in post-TRIPS period (after1995)
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Research Problem and Questions

1) What is the significance of IPR in Indian pharma industry?
2) How amended patent act is changing the scope of Indian pharma industry?
3) What is the effect of amended patent act on Indian pharmaceutical product?
Importance of the Study
In order to be evidence for the Indian Pharma companies in a path that have huge benefits by amended Patent act on the marketing activity in the way that best fit the consumers. This study will be useful for providing importance and scope of IPR for the Indian pharma companies for patenting the molecule. E sources: Internet, sites, journals, publications, articles, online research papers etc.
Data Analysis procedure: The field survey and personal interview technique adopted for data collection and collected data has been tabulated and presented with the help of graphs, tables and charts. Both descriptive and inferential statistics were used in presenting and analyzing the data. Descriptive tools such as frequency counts, mean scores, percentages were calculated for the statements on the questionnaire in order to determine the impact and its related issues.
Statistical Technique: Chi-square is a statistical test commonly used to compare observed data with expected data to obtain according to a specific hypothesis. The test allows research student to compare a collection of categorical data with some theoretical expected distribution. 
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